4 Aug 2026
Every registered trial, pulled straight from the registry
Each program page now lists every study on ClinicalTrials.gov that names the compound or its development code, with phase, recruitment status, enrolment and primary completion date. That is 44 studies across the nine active programs and the three discontinued ones, up from the 9 cited before.
The registry data is refreshed mechanically rather than by hand, and published alongside the main dataset at /trials.json. ALKS 4510 and ALKS 7290 return no registry records; both are listed on Alkermes' pipeline page but have no public study.
4 Aug 2026
Site rebuilt: a page per program, plus explainers
Every program now has its own page with its trial registry IDs, sources and common questions. Five background explainers cover the drug class, narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, the agonist/antagonist distinction, and how this class compares to current treatments.
The underlying dataset is published at /data.json and is free to use with attribution.
4 Aug 2026
Eight uncertain entries verified against primary sources
Eight programs previously flagged as needing re-checking were verified against ClinicalTrials.gov records and sponsor pipeline pages, and corrected where they were wrong. Notable corrections: cleminorexton moved to Phase 3 following the registrational study that opened 29 May 2026; ORX489 moved from IND-enabling to Phase 1; E2086 moved to Phase 2.
TAK-360 stays at Phase 2 despite its extension study NCT07646678 carrying a Phase 2/3 registry label, because that study is not a pivotal efficacy trial.
30 Jul 2026
Oveporexton still under FDA review
Takeda's Q1 FY2026 earnings release confirmed the US application remains under review, with launch preparations underway for the second half of 2026. The PDUFA target remains a third-quarter window with no named day.
22 Jul 2026
Oveporexton approved in China — a first for the class
Chinese regulators approved oveporexton, brand name ORZEYFUL, for adults and adolescents aged 16 and over with narcolepsy type 1. It is the first oral OX2R-selective agonist approved in any country.
24 Jun 2026
Eli Lilly completes its acquisition of Centessa
Centessa Pharmaceuticals became a wholly owned Eli Lilly subsidiary, moving cleminorexton, ORX142 and ORX489 into Lilly's portfolio.
1 Apr 2026
Alixorexton enters Phase 3
Alkermes opened the Brilliance program: Study 302 and Study 304 in narcolepsy type 1, Study 303 in narcolepsy type 2. Vibrance-3 continues at Phase 2 in idiopathic hypersomnia.